FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293092869> ?p ?o ?g. }

• W4293092869 endingPage "648" @default.
• W4293092869 startingPage "644" @default.
• W4293092869 abstract "B-cell maturation antigen (BCMA) is selectively expressed as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of patients with MM. The bispecific antibodies teclistamab (BCMA×CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]×CD3) are in clinical development as therapies for MM. Using data from patients with relapsed/refractory MM (N=300) who participated in phase 1 studies of teclistamab (NCT03145181) or talquetamab (NCT03399799), baseline serum sBCMA levels were quantitatively analyzed relative to response to treatment, percentage of bone marrow plasma cells (BMPCs), and cytogenetic risk. By cycle 3 day 1 of treatment, sBCMA levels declined from baseline in 50 (88%) of 57 responders and 49 (98%) of 50 responders to teclistamab and talquetamab, respectively. Depth of response correlated with the magnitude of sBCMA reduction. In contrast, sBCMA increased in 33 (80%) of 41 patients and 24 (49%) of 49 patients who did not respond to teclistamab or talquetamab, respectively. Baseline sBCMA levels correlated with the percentage of BMPC; patients with extramedullary plasmacytomas who had low levels of BMPC (≤10%) tended to have high baseline sBCMA levels (≥400 ng/mL), based on limited data. Baseline sBCMA levels and changes in sBCMA levels at cycle 3 day 1 were similar in patients with high- and standard-risk cytogenetics treated with teclistamab or talquetamab. These results support the use of sBCMA as a potential surrogate marker of tumor burden and treatment response in MM." @default.
• W4293092869 created "2022-08-26" @default.
• W4293092869 creator A5000092188 @default.
• W4293092869 creator A5006758104 @default.
• W4293092869 creator A5011533368 @default.
• W4293092869 creator A5020367558 @default.
• W4293092869 creator A5020819058 @default.
• W4293092869 creator A5022683984 @default.
• W4293092869 creator A5028976895 @default.
• W4293092869 creator A5034440644 @default.
• W4293092869 creator A5039555935 @default.
• W4293092869 creator A5050233167 @default.
• W4293092869 creator A5055528381 @default.
• W4293092869 creator A5056008039 @default.
• W4293092869 creator A5057090502 @default.
• W4293092869 creator A5067790229 @default.
• W4293092869 creator A5069748830 @default.
• W4293092869 creator A5072062495 @default.
• W4293092869 creator A5091071176 @default.
• W4293092869 date "2023-02-21" @default.
• W4293092869 modified "2023-10-16" @default.
• W4293092869 title "Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma" @default.
• W4293092869 cites W1661103064 @default.
• W4293092869 cites W1832162035 @default.
• W4293092869 cites W2003734726 @default.
• W4293092869 cites W2044436186 @default.
• W4293092869 cites W2056066615 @default.
• W4293092869 cites W2069282346 @default.
• W4293092869 cites W2100718970 @default.
• W4293092869 cites W2127132803 @default.
• W4293092869 cites W2145345130 @default.
• W4293092869 cites W2471662063 @default.
• W4293092869 cites W2562243521 @default.
• W4293092869 cites W2807637103 @default.
• W4293092869 cites W2902853390 @default.
• W4293092869 cites W2975075750 @default.
• W4293092869 cites W3006655689 @default.
• W4293092869 cites W3087111554 @default.
• W4293092869 cites W3087735636 @default.
• W4293092869 cites W3133229959 @default.
• W4293092869 cites W3162928291 @default.
• W4293092869 cites W3188071931 @default.
• W4293092869 cites W4282033105 @default.
• W4293092869 doi "https://doi.org/10.1182/bloodadvances.2022007625" @default.
• W4293092869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36006441" @default.
• W4293092869 hasPublicationYear "2023" @default.
• W4293092869 type Work @default.
• W4293092869 citedByCount "5" @default.
• W4293092869 countsByYear W42930928692022 @default.
• W4293092869 countsByYear W42930928692023 @default.
• W4293092869 crossrefType "journal-article" @default.
• W4293092869 hasAuthorship W4293092869A5000092188 @default.
• W4293092869 hasAuthorship W4293092869A5006758104 @default.
• W4293092869 hasAuthorship W4293092869A5011533368 @default.
• W4293092869 hasAuthorship W4293092869A5020367558 @default.
• W4293092869 hasAuthorship W4293092869A5020819058 @default.
• W4293092869 hasAuthorship W4293092869A5022683984 @default.
• W4293092869 hasAuthorship W4293092869A5028976895 @default.
• W4293092869 hasAuthorship W4293092869A5034440644 @default.
• W4293092869 hasAuthorship W4293092869A5039555935 @default.
• W4293092869 hasAuthorship W4293092869A5050233167 @default.
• W4293092869 hasAuthorship W4293092869A5055528381 @default.
• W4293092869 hasAuthorship W4293092869A5056008039 @default.
• W4293092869 hasAuthorship W4293092869A5057090502 @default.
• W4293092869 hasAuthorship W4293092869A5067790229 @default.
• W4293092869 hasAuthorship W4293092869A5069748830 @default.
• W4293092869 hasAuthorship W4293092869A5072062495 @default.
• W4293092869 hasAuthorship W4293092869A5091071176 @default.
• W4293092869 hasBestOaLocation W42930928691 @default.
• W4293092869 hasConcept C126322002 @default.
• W4293092869 hasConcept C142424586 @default.
• W4293092869 hasConcept C143998085 @default.
• W4293092869 hasConcept C2776364478 @default.
• W4293092869 hasConcept C71924100 @default.
• W4293092869 hasConcept C86803240 @default.
• W4293092869 hasConcept C87355193 @default.
• W4293092869 hasConceptScore W4293092869C126322002 @default.
• W4293092869 hasConceptScore W4293092869C142424586 @default.
• W4293092869 hasConceptScore W4293092869C143998085 @default.
• W4293092869 hasConceptScore W4293092869C2776364478 @default.
• W4293092869 hasConceptScore W4293092869C71924100 @default.
• W4293092869 hasConceptScore W4293092869C86803240 @default.
• W4293092869 hasConceptScore W4293092869C87355193 @default.
• W4293092869 hasIssue "4" @default.
• W4293092869 hasLocation W42930928691 @default.
• W4293092869 hasLocation W42930928692 @default.
• W4293092869 hasLocation W42930928693 @default.
• W4293092869 hasOpenAccess W4293092869 @default.
• W4293092869 hasPrimaryLocation W42930928691 @default.
• W4293092869 hasRelatedWork W2068316626 @default.
• W4293092869 hasRelatedWork W2110818089 @default.
• W4293092869 hasRelatedWork W2351796763 @default.
• W4293092869 hasRelatedWork W2351985199 @default.
• W4293092869 hasRelatedWork W2403502999 @default.
• W4293092869 hasRelatedWork W2435227317 @default.
• W4293092869 hasRelatedWork W2567738959 @default.
• W4293092869 hasRelatedWork W2923882796 @default.
• W4293092869 hasRelatedWork W4297834875 @default.

• next